PWM
CRSP icon

PRW Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

PRW Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-125
Closed -$4K – 191
2019
Q1 		$4K Hold
125
– – ﹤0.01% 412
2018
Q4 		$4K Buy
+125
New +$4.35K 0.01% 406

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PRW Wealth Management's CRSP Position: Q2 2019 in Review

PRW Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q2 2019, closing a stake of 125 shares — an estimated $4K sold.

PRW Wealth Management first reported a position in CRSP in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 181 funds tracked by Wall St. Rank hold CRSP as of Q2 2019.

  • PRW Wealth Management reported no remaining CRISPR Therapeutics position as of Q2 2019 after selling out during the quarter.
  • PRW Wealth Management sold 125 CRISPR Therapeutics shares in Q2 2019, an estimated $4K.
  • PRW Wealth Management first reported a position in CRISPR Therapeutics in Q4 2018 and held it in 2 quarters.
  • PRW Wealth Management's CRISPR Therapeutics position peaked at $4K in Q1 2019.
  • 181 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2019.

Based on PRW Wealth Management's 13F filing for Q2 2019, filed 12 Aug 2019.